KR102019974B1 - A composition for preventing, improving or treating alcoholic gastro-intestinal disease comprising the extracts from licorice and dandelion - Google Patents
A composition for preventing, improving or treating alcoholic gastro-intestinal disease comprising the extracts from licorice and dandelion Download PDFInfo
- Publication number
- KR102019974B1 KR102019974B1 KR1020170104866A KR20170104866A KR102019974B1 KR 102019974 B1 KR102019974 B1 KR 102019974B1 KR 1020170104866 A KR1020170104866 A KR 1020170104866A KR 20170104866 A KR20170104866 A KR 20170104866A KR 102019974 B1 KR102019974 B1 KR 102019974B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- licorice
- mixture
- dandelion
- alcohol
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 93
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 title claims abstract description 43
- 208000018522 Gastrointestinal disease Diseases 0.000 title claims abstract description 15
- 230000001476 alcoholic effect Effects 0.000 title claims abstract description 14
- 239000000284 extract Substances 0.000 title claims description 58
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 title claims description 49
- 240000001949 Taraxacum officinale Species 0.000 title claims description 11
- 208000010643 digestive system disease Diseases 0.000 title claims description 7
- 208000018685 gastrointestinal system disease Diseases 0.000 title claims description 7
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 title abstract description 39
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 title abstract description 39
- 229940010454 licorice Drugs 0.000 title abstract description 39
- 240000004670 Glycyrrhiza echinata Species 0.000 title 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 67
- 238000011282 treatment Methods 0.000 claims abstract description 27
- 230000002496 gastric effect Effects 0.000 claims abstract description 25
- 230000036541 health Effects 0.000 claims abstract description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 13
- 239000004480 active ingredient Substances 0.000 claims abstract description 11
- 230000002265 prevention Effects 0.000 claims abstract description 11
- 230000006872 improvement Effects 0.000 claims abstract description 10
- 235000013376 functional food Nutrition 0.000 claims abstract description 6
- 241000245665 Taraxacum Species 0.000 claims description 41
- 244000303040 Glycyrrhiza glabra Species 0.000 claims description 40
- 208000007882 Gastritis Diseases 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 208000007107 Stomach Ulcer Diseases 0.000 claims description 15
- 230000006378 damage Effects 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 11
- 201000005917 gastric ulcer Diseases 0.000 claims description 10
- 240000008917 Glycyrrhiza uralensis Species 0.000 claims description 6
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 claims description 6
- 208000027418 Wounds and injury Diseases 0.000 claims description 5
- 208000014674 injury Diseases 0.000 claims description 5
- 235000006754 Taraxacum officinale Nutrition 0.000 claims description 4
- 230000001154 acute effect Effects 0.000 claims description 4
- 208000023652 chronic gastritis Diseases 0.000 claims description 4
- 239000012046 mixed solvent Substances 0.000 claims description 4
- 235000017443 Hedysarum boreale Nutrition 0.000 claims description 3
- 235000007858 Hedysarum occidentale Nutrition 0.000 claims description 3
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 claims description 3
- 235000015872 dietary supplement Nutrition 0.000 claims description 2
- 235000020691 dandelion extract Nutrition 0.000 abstract description 33
- 229940067866 dandelion extract Drugs 0.000 abstract description 32
- 239000001845 taraxacum officinale leaf extract Substances 0.000 abstract description 32
- 206010061218 Inflammation Diseases 0.000 abstract description 16
- 230000004054 inflammatory process Effects 0.000 abstract description 15
- 230000002195 synergetic effect Effects 0.000 abstract description 9
- 241000202807 Glycyrrhiza Species 0.000 abstract description 5
- 239000001649 glycyrrhiza glabra l. absolute Substances 0.000 description 26
- 229940051810 licorice root extract Drugs 0.000 description 26
- 235000020725 licorice root extract Nutrition 0.000 description 26
- 230000000694 effects Effects 0.000 description 25
- 238000002360 preparation method Methods 0.000 description 22
- 210000001519 tissue Anatomy 0.000 description 16
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 15
- 108010082126 Alanine transaminase Proteins 0.000 description 15
- 239000003814 drug Substances 0.000 description 15
- 229940069445 licorice extract Drugs 0.000 description 14
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 13
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 239000000843 powder Substances 0.000 description 10
- 239000003085 diluting agent Substances 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 206010017856 Gastritis alcoholic Diseases 0.000 description 8
- 201000005988 alcoholic gastritis Diseases 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 238000000605 extraction Methods 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 7
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 229940124597 therapeutic agent Drugs 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- QAPSNMNOIOSXSQ-YNEHKIRRSA-N 1-[(2r,4s,5r)-4-[tert-butyl(dimethyl)silyl]oxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O[Si](C)(C)C(C)(C)C)C1 QAPSNMNOIOSXSQ-YNEHKIRRSA-N 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 235000013373 food additive Nutrition 0.000 description 5
- 239000002778 food additive Substances 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 4
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 235000015067 sauces Nutrition 0.000 description 4
- 235000014347 soups Nutrition 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 240000005979 Hordeum vulgare Species 0.000 description 3
- 235000007340 Hordeum vulgare Nutrition 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 240000003768 Solanum lycopersicum Species 0.000 description 3
- 244000299461 Theobroma cacao Species 0.000 description 3
- 230000009858 acid secretion Effects 0.000 description 3
- 235000015278 beef Nutrition 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 235000014121 butter Nutrition 0.000 description 3
- 235000014171 carbonated beverage Nutrition 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 210000001156 gastric mucosa Anatomy 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 description 3
- 235000008960 ketchup Nutrition 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 235000012149 noodles Nutrition 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000003449 preventive effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241001107116 Castanospermum australe Species 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 208000005577 Gastroenteritis Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 235000004347 Perilla Nutrition 0.000 description 2
- 244000124853 Perilla frutescens Species 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- HWXBTNAVRSUOJR-UHFFFAOYSA-N alpha-hydroxyglutaric acid Natural products OC(=O)C(O)CCC(O)=O HWXBTNAVRSUOJR-UHFFFAOYSA-N 0.000 description 2
- 229940009533 alpha-ketoglutaric acid Drugs 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 229940069428 antacid Drugs 0.000 description 2
- 239000003159 antacid agent Substances 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 230000004596 appetite loss Effects 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 235000021279 black bean Nutrition 0.000 description 2
- 235000007215 black sesame Nutrition 0.000 description 2
- 208000034158 bleeding Diseases 0.000 description 2
- 235000008429 bread Nutrition 0.000 description 2
- 235000021329 brown rice Nutrition 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000010411 cooking Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 210000004211 gastric acid Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229960002989 glutamic acid Drugs 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 231100000234 hepatic damage Toxicity 0.000 description 2
- 235000015243 ice cream Nutrition 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000008818 liver damage Effects 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 235000021266 loss of appetite Nutrition 0.000 description 2
- 208000019017 loss of appetite Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 229940126409 proton pump inhibitor Drugs 0.000 description 2
- 239000000612 proton pump inhibitor Substances 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 240000001879 Digitalis lutea Species 0.000 description 1
- 235000011511 Diospyros Nutrition 0.000 description 1
- 244000236655 Diospyros kaki Species 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 240000008397 Ganoderma lucidum Species 0.000 description 1
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 1
- 206010017788 Gastric haemorrhage Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- ALLWOAVDORUJLA-UHFFFAOYSA-N Rebamipida Chemical compound C=1C(=O)NC2=CC=CC=C2C=1CC(C(=O)O)NC(=O)C1=CC=C(Cl)C=C1 ALLWOAVDORUJLA-UHFFFAOYSA-N 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000007705 chemical test Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 239000000498 cooling water Substances 0.000 description 1
- 235000012495 crackers Nutrition 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 235000013882 gravy Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000024557 hepatobiliary disease Diseases 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 235000019462 natural additive Nutrition 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- -1 pH adjusters Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 238000004161 plant tissue culture Methods 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 229950004535 rebamipide Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Botany (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 감초 및 노랑민들레 추출물을 유효성분으로 함유하는 알코올성 위장관질환의 예방, 개선 또는 치료용 조성물에 관한 것으로, 더욱 상세하게는 알코올로 유발된 위 조직의 염증 완화에 상승효과(synergistic effect)를 나타내는 감초 및 노랑민들레 추출물의 혼합물을 이용하여 알코올성 위장관질환의 예방, 개선 또는 치료용 약학적 조성물 및 건강기능식품을 제공한다.The present invention relates to a composition for the prevention, improvement or treatment of alcoholic gastrointestinal diseases containing licorice and yellow dandelion extract as an active ingredient, and more particularly, has a synergistic effect in reducing inflammation of alcohol-induced gastric tissue. Using a mixture of licorice and yellow dandelion extract to provide a pharmaceutical composition and health functional food for the prevention, improvement or treatment of alcoholic gastrointestinal diseases.
Description
본 발명은 감초 및 노랑민들레 추출물을 유효성분으로 함유하는 알코올성 위장관질환의 예방, 개선 또는 치료용 조성물에 관한 것으로, 더욱 상세하게는 알코올로 유발된 위 조직의 염증 완화에 상승효과(synergistic effect)를 나타내는 감초 및 노랑민들레 추출물의 혼합물을 이용하여 알코올성 위장관질환의 예방, 개선 또는 치료용 약학적 조성물 및 건강기능식품을 제공한다.The present invention relates to a composition for the prevention, improvement or treatment of alcoholic gastrointestinal diseases containing licorice and yellow dandelion extract as an active ingredient, and more particularly, has a synergistic effect in reducing inflammation of alcohol-induced gastric tissue. Using a mixture of licorice and yellow dandelion extract to provide a pharmaceutical composition and health functional food for the prevention, improvement or treatment of alcoholic gastrointestinal diseases.
우리나라의 경우 20세 이상 성인 남자의 음주율은 83.3%로 매우 높고 여성의 음주율 또한 54.9%로 급격히 증가하는 추세에 있으며, 잘못된 음주문화로 인하여 과음에 심각하게 노출되어 있다. 알코올의 과다 섭취로 인한 폐해는 위염 및 간질환을 비롯하여 각종 질환의 병인이 됨은 물론 개인, 가정, 사회의 정서와 생활에 부정적인 영향을 미침으로써 국가적으로 막대한 경제, 사회적 손실을 야기하고 있다.In Korea, the drinking rate of males over 20 years of age is very high (83.3%), and the drinking rate of females is also rapidly increasing to 54.9%. The harm caused by excessive intake of alcohol is not only a cause of gastritis and liver disease, but also negatively affects the emotions and lives of individuals, families, and society, causing huge economic and social losses.
알코올성 위염은 알코올로 인한 만성적인 자극에 의해 위 점막이 손상된 상태를 일컫는다. 알코올성 위염에 걸리면 소화가 잘 되지 않고 쓰린 느낌을 호소하는 경우도 있지만 대부분 특별한 증상이 없다가 내시경 검사와 초음파 검사를 통해 심각한 증상이 발견된다. 만성적으로 술을 마시는 경우 위염뿐만 아니라 췌장이나 간 등도 손상시켜 관련질환을 유발하며, 또한 식도암, 위암, 대장암의 위험도 높아진다.Alcoholic gastritis is a condition in which the gastric mucosa is damaged by chronic stimulation caused by alcohol. Alcoholic gastritis is often difficult to digest and complains of a bitter feeling, but most cases have no symptoms, and serious symptoms are found through endoscopy and ultrasound. If you drink alcohol chronically, not only gastritis, but also damage the pancreas and liver, causing related diseases, and also increases the risk of esophageal cancer, stomach cancer, colon cancer.
특히, 알코올로 인한 위염 및 위궤양은 가장 주의를 요하는데, 알코올은 위벽의 세포를 자극해 산 분비를 증가시키며, 과도한 알코올 섭취는 위점막의 부종을 발생시켜 출혈을 일으키고 염증세포들의 생성을 유도한다. 또한, 산화적 스트레스로 인한 괴사 혹은 세포사멸을 유도하여 위점막을 손상시키고, 위출혈이 나타나게 된다.In particular, gastritis and gastric ulcers caused by alcohol require the most attention, which stimulates the cells of the stomach wall to increase acid secretion, and excessive alcohol intake causes swelling of the gastric mucosa, causing bleeding and inducing the production of inflammatory cells. . In addition, necrosis or apoptosis caused by oxidative stress damages the gastric mucosa, and gastric bleeding appears.
종래의 위염 및 위궤양의 치료제로는 과다 분비된 위산을 중화시키는 제산제(antacid), 산 분비 억제 목적의 히스타민 길항제(histamine antagonist), 프로톤 펌프 저해제(proton pump inhibitor), 콜린 억제제, 위내막의 내성을 증가시키고 회복을 돕는 위점막보호제 등이 있다. 다만, 이와 같은 치료제들은 합성 의약품으로 식욕감퇴, 무력감, 알레르기 등의 부작용이 발생하는 문제점이 있었다.Conventional treatments for gastritis and gastric ulcers include antacids that neutralize excessive secreted gastric acid, histamine antagonists for acid secretion, proton pump inhibitors, choline inhibitors, and gastrointestinal resistance. Gastric mucoprotectants that can help increase and recover. However, these therapeutic agents have a problem that side effects such as loss of appetite, helplessness, allergies, etc. as synthetic drugs.
이에 따라, 대한민국 공개특허 제10-2009-0046425호(천마 추출물을 함유하는 위염 또는 위궤양의 예방 또는 치료용 조성물), 대한민국 등록특허 제10-1091025호(복분자 추출물을 함유하는 비스테로이드성 항염증제에 의해 유발된 위염 및 위궤양 예방 및 치료용 조성물), 대한민국 공개특허 제10-2012-0051904호(옻나무 추출물을 포함하는 위염 및 위궤양 치료제 조성물), 대한민국 등록특허 제10-1204981호(고로쇠 수액을 함유하는 위염 및 위궤양의 예방 및 치료용 조성물) 등 위염 및 위궤양의 예방 및 치료 효과가 있는 천연 추출물에 대한 관심이 높아지고 있다. Accordingly, Republic of Korea Patent Publication No. 10-2009-0046425 (composition for the prevention or treatment of gastritis or gastric ulcer containing cheonma extract), Republic of Korea Patent No. 10-1091025 (non-steroidal anti-inflammatory agent containing bokbunja extract Induced gastritis and gastric ulcer prevention and treatment composition), Republic of Korea Patent Publication No. 10-2012-0051904 (Gastroenteritis and gastric ulcer composition comprising lacquer extract), Republic of Korea Patent No. 10-1204981 (Gastroenteritis containing gorgo sap) And compositions for the prevention and treatment of gastric ulcers), such as natural extracts that have the effect of preventing and treating gastritis and gastric ulcers.
이러한 배경하에, 본 발명자들은 감초와 노랑민들레 추출물의 혼합물이 알코올성 위장관질환의 완화에 상승효과를 나타냄을 확인하고 본 발명을 완성하였다.Under this background, the present inventors have confirmed that the mixture of licorice and yellow dandelion extract has a synergistic effect on the alleviation of alcoholic gastrointestinal diseases and completed the present invention.
본 발명은 상기와 같은 문제점을 해결하기 위해 안출된 것으로, 감초 및 노랑민들레 추출물의 혼합물을 이용하여 알코올성 위장관질환을 예방, 개선 또는 치료하기 위한 조성물을 제공하는데 목적이 있다.The present invention has been made to solve the above problems, it is an object to provide a composition for preventing, ameliorating or treating alcoholic gastrointestinal diseases using a mixture of licorice and yellow dandelion extract.
상술한 과제를 해결하기 위해, 본 발명은 감초(Glycyrrhiza uralensis) 및 노랑민들레(Taraxacum officinale) 추출물의 혼합물을 유효성분으로 함유하는 알코올성 위장관질환의 예방 또는 치료용 약학적 조성물을 제공한다.In order to solve the above problems, the present invention is a licorice ( Glycyrrhiza It provides a pharmaceutical composition for the prevention or treatment of alcoholic gastrointestinal diseases containing a mixture of uralensis ) and extracts of Taraxacum officinale as an active ingredient.
본 발명은 또한, 감초(Glycyrrhiza uralensis) 및 노랑민들레(Taraxacum officinale) 추출물의 혼합물을 유효성분으로 함유하는 알코올성 위장관질환의 예방 또는 개선용 건강기능식품 조성물을 제공한다.The invention also relates to licorice ( Glycyrrhiza uralensis ) and yellow dandelion ( Taraxacum) officinale) provides a mixture of an alcoholic gastrointestinal disease preventing or improving functional health food composition for containing, as an active ingredient of the extract.
본 발명의 바람직한 일실시예에 따르면, 상기 감초의 부위는 뿌리이고, 상기 노랑민들레의 부위는 지상부일 수 있다.According to a preferred embodiment of the present invention, the part of the licorice is the root, the part of the yellow dandelion may be the ground portion.
본 발명의 바람직한 다른 일실시예에 따르면, 상기 감초 및 노랑민들레 추출물은 물, C1~C4의 알코올 또는 이들의 혼합용매로 추출할 수 있다.According to another preferred embodiment of the present invention, the licorice and yellow dandelion extract may be extracted with water, C 1 ~ C 4 alcohol or a mixed solvent thereof.
본 발명의 바람직한 또 다른 일실시예에 따르면, 상기 감초와 노랑민들레 추출물은 1:0.25 내지 1:4의 중량비로 함유될 수 있다.According to another preferred embodiment of the present invention, the licorice and yellow dandelion extract may be contained in a weight ratio of 1: 0.25 to 1: 4.
본 발명의 바람직한 다른 일실시예에 따르면, 상기 알코올성 위장관질환은 알코올에 의해 유도된 급성 위점막 손상, 위궤양, 급성 위염 및 만성 위염으로 이루어진 군으로부터 선택한 1종 이상일 수 있다.According to another preferred embodiment of the present invention, the alcoholic gastrointestinal disease may be at least one selected from the group consisting of alcohol-induced acute gastric mucosal injury, gastric ulcer, acute gastritis and chronic gastritis.
본 발명에 따른 감초 및 노랑민들레 추출물을 특정 중량비 범위로 혼합한 조성물은 알코올에 의해 손상된 위 조직의 염증 완화에 대한 상승효과가 우수하여 알코올성 위염 또는 위궤양을 예방, 개선 또는 치료하는데 유용하다. 또한, 상기 본 발명의 혼합 조성물은 간 조직에서 GOT 및 GPT의 활성을 저해하는 효과가 있어, 추가로 알코올성 간 손상에 대한 예방 효과를 나타낸다.The composition of the licorice and yellow dandelion extract according to the present invention mixed in a specific weight ratio range is excellent in synergistic effect on relieving inflammation of gastric tissue damaged by alcohol, and is useful for preventing, improving or treating alcoholic gastritis or gastric ulcer. In addition, the mixed composition of the present invention has the effect of inhibiting the activity of GOT and GPT in liver tissue, further showing a preventive effect against alcoholic liver damage.
나아가, 본 발명의 조성물은 천연물 소재의 추출물을 유효성분으로 하여 인체에 안전하고, 부작용이 적어 의약품, 의약외품 및 건강기능식품등의 개발에 소재로 적합하다.Furthermore, the composition of the present invention is safe for the human body using the extract of the natural material as an active ingredient, less side effects are suitable as a material for the development of medicines, quasi-drugs and health functional foods.
도 1은 알코올 투여로 위염이 유발된 쥐의 위 조직에서 감초와 노랑민들레 추출물을 다양한 중량비로 혼합한 조성물의 처리에 따른 염증 완화 정도를 보여주는 사진이다.
도 2는 도 1의 결과를 바탕으로 각 군의 위 염증 발생 면적을 백분율로 계산하여 나타낸 그래프이다.
도 3은 알코올 투여로 위염이 유발된 쥐의 위 조직에서 감초와 노랑민들레 추출물을 다양한 중량비로 혼합한 조성물의 처리에 따른 iNOS(inducible nitric oxide synthase) 단백질의 발현 억제 효과를 나타낸 그래프이다.
도 4는 알코올 투여로 간 손상을 일으킨 쥐에서 감초와 노랑민들레 추출물을 다양한 중량비로 혼합한 조성물의 처리에 따른 GOP 수치(좌) 및 GPT 수치(우) 저해 효과를 나타낸 그래프이다.Figure 1 is a photograph showing the degree of inflammation relief according to the treatment of the composition of licorice and yellow dandelion extract in various weight ratios in the gastric tissue of the rat gastritis induced by alcohol administration.
FIG. 2 is a graph showing the calculated percentage of gastric inflammation in each group based on the results of FIG. 1.
Figure 3 is a graph showing the effect of inhibiting the expression of inducible nitric oxide synthase (iNOS) protein according to the treatment of a mixture of licorice and yellow dandelion extract in various weight ratios in the gastric tissue of rat gastric inflammation induced by alcohol administration.
Figure 4 is a graph showing the effect of inhibiting the GOP (left) and GPT (right) according to the treatment of a composition mixed with licorice and yellow dandelion extract in various weight ratio in rats causing liver damage by alcohol administration.
이하, 본 발명을 더욱 상세히 설명한다.Hereinafter, the present invention will be described in more detail.
상술한 바와 같이, 종래의 위염 및 위궤양의 치료제로는 과다 분비된 위산을 중화시키는 제산제(antacid), 산 분비 억제 목적의 히스타민 길항제(histamine antagonist), 프로톤 펌프 저해제(proton pump inhibitor), 콜린 억제제, 위내막의 내성을 증가시키고 회복을 돕는 위점막보호제 등이 있다. 다만, 이와 같은 치료제들은 합성 의약품으로 식욕감퇴, 무력감, 알레르기 등의 부작용이 발생하는 문제점이 있어 부작용이 없는 천연 추출물을 이용한 위염 또는 위궤양 치료제에 대한 개발이 지속적으로 요구되고 있다.As described above, conventional therapeutic agents for gastritis and gastric ulcers include antacids that neutralize excessive secreted gastric acid, histamine antagonists for acid secretion, proton pump inhibitors, choline inhibitors, Gastric mucoprotective agents that increase the resistance of the gastric lining and help recovery. However, these therapeutic agents have a problem in that side effects such as loss of appetite, helplessness, and allergies are caused by synthetic drugs, and there is a continuous demand for development of a gastritis or gastric ulcer therapeutic agent using natural extracts without side effects.
이에, 본 발명자들은 감초와 노랑민들레 추출물의 혼합물을 유효성분으로 함유하는 조성물을 제공함으로써 상술한 문제의 해결방안을 모색하였다. 본 발명에 따른 감초 및 노랑민들레 추출물을 특정 중량비 범위로 혼합한 조성물은 알코올에 의해 손상된 위 조직의 염증 완화에 대한 상승효과가 우수하여 알코올성 위염 또는 위궤양을 예방, 개선 또는 치료하는데 유용하다. 또한, 상기 본 발명의 혼합 조성물은 알코올에 의해 손상된 간 조직에서 GOT 및 GPT의 활성을 저해하는 효과가 있어, 추가로 알코올성 간 손상을 개선시킬 수 있다.Accordingly, the present inventors sought solutions to the above problems by providing a composition containing a mixture of licorice and yellow dandelion extract as an active ingredient. The composition of the licorice and yellow dandelion extract according to the present invention mixed in a specific weight ratio range is excellent in synergistic effect on relieving inflammation of gastric tissue damaged by alcohol, and is useful for preventing, improving or treating alcoholic gastritis or gastric ulcer. In addition, the mixed composition of the present invention has the effect of inhibiting the activity of GOT and GPT in the liver tissue damaged by alcohol, it can further improve alcoholic liver damage.
본 발명에서 사용되는 용어는 다음과 같이 정의된다.The terms used in the present invention are defined as follows.
용어 “약학적 조성물(pharmaceutical composition)”은 본 발명의 감초와 노랑민들레 추출물의 혼합물에 희석제 또는 담체와 같은 다른 화학 성분들을 혼합한 혼합물을 의미한다.The term “pharmaceutical composition” refers to a mixture of other chemical components such as diluents or carriers in a mixture of licorice and yellow dandelion extracts of the present invention.
용어 “담체(carrier)”는 세포 또는 조직 내로의 화합물의 부가를 용이하게 하는 화합물로 정의된다. 예를 들어, 디메틸술폭사이드(DMSO)는 생물체의 세포 또는 조직 내로의 많은 유기 화합물들의 투입을 용이하게 하는 통상 사용되는 담체이다.The term “carrier” is defined as a compound that facilitates the addition of a compound into a cell or tissue. For example, dimethyl sulfoxide (DMSO) is a commonly used carrier that facilitates the incorporation of many organic compounds into cells or tissues of an organism.
용어 “희석제(diluent)”는 대상 화합물의 생물학적 활성 형태를 안정화시킬 뿐만 아니라, 화합물을 용해시키게 되는 물에서 희석되는 화합물로 정의된다. 버퍼 용액에 용해되어 있는 염은 당해 분야에서 희석제로 사용된다. 통상 사용되는 버퍼 용액은 포스페이트 버퍼 식염수이며, 이는 인간 용액의 염 상태를 모방하고 있기 때문이다. 버퍼 염은 낮은 농도에서 용액의 pH를 제어할 수 있기 때문에, 버퍼 희석제가 화합물의 생물학적 활성을 변형하는 일은 드물다.The term “diluent” is defined as a compound that not only stabilizes the biologically active form of the compound of interest, but also is diluted in water to dissolve the compound. Salts dissolved in buffer solutions are used as diluents in the art. A commonly used buffer solution is phosphate buffered saline, because it mimics the salt state of human solutions. Because buffer salts can control the pH of a solution at low concentrations, buffer diluents rarely modify the biological activity of a compound.
용어 “치료”는 이롭거나 바람직한 임상적 결과를 수득하기 위한 접근을 의미한다. 본 발명의 목적을 위해서, 이롭거나 바람직한 임상적 결과는 비제한적으로, 증상의 완화, 질병 범위의 감소, 질병 상태의 안정화(즉, 악화되지 않음), 질병 진행의 지연 또는 속도의 감소, 질병 상태의 개선 또는 일시적 완화 및 경감 (부분적이거나 전체적으로), 검출가능하거나 또는 검출되지 않거나의 여부를 포함한다. 또한, “치료”는 치료를 받지 않았을 때 예상되는 생존율과 비교하여 생존율을 늘이는 것을 의미할 수도 있다. “치료”는 치료학적 치료 및 예방적 또는 예방조치 방법 모두를 가리킨다. 상기 치료들은 예방되는 장애뿐만 아니라 이미 발생한 장애에 있어서 요구되는 치료를 포함한다. 질병을 “완화(alleviating)”하는 것은 치료를 하지 않은 경우와 비교하여, 질병상태의 범위 및/또는 바람직하지 않은 임상적 징후가 감소되거나 및/또는 진행의 시간적 추이(time course)가 늦춰지거나 길어지는 것을 의미한다.The term “treatment” refers to an approach for obtaining beneficial or desirable clinical results. For the purposes of the present invention, beneficial or desirable clinical outcomes include, but are not limited to, alleviation of symptoms, reduction of disease range, stabilization of disease state (ie, not worsening), delay or slowing of disease progression, disease state Improvement or temporary mitigation and alleviation (partially or wholly), detectable or not detected. "Treatment" may also mean increasing survival compared to the expected survival rate without treatment. "Treatment" refers to both therapeutic treatment and preventive or preventive measures. Such treatments include the treatments required for the disorders that have already occurred as well as the disorders to be prevented. “Alleviating” a disease may reduce the extent of disease status and / or undesirable clinical signs and / or slow or lengthen the time course of progression as compared to untreated treatment. It means losing.
본 발명에서 사용되는 모든 기술용어는, 달리 정의되지 않는 이상, 본 발명의 관련 분야에서 통상의 당업자가 일반적으로 이해하는 바와 같은 의미로 사용된다. 또한 본 명세서에는 바람직한 방법이나 시료가 기재되나, 이와 유사하거나 동등한 것들도 본 발명의 범주에 포함된다.All technical terms used in the present invention, unless defined otherwise, are used in the meaning as commonly understood by those skilled in the art in the related field of the present invention. Also described herein are preferred methods or samples, but similar or equivalent ones are within the scope of the present invention.
본 발명은 감초(Glycyrrhiza uralensis) 및 노랑민들레(Taraxacum officinale) 추출물의 혼합물을 유효성분으로 함유하는 알코올성 위장관질환의 예방 또는 치료용 약학적 조성물을 제공한다.The present invention is licorice ( Glycyrrhiza uralensis ) and yellow dandelion ( Taraxacum) officinale) provides the alcohol gastrointestinal disease prevention or treatment a pharmaceutical composition containing as an active ingredient of the mixture of the extract.
또한, 본 발명은 감초(Glycyrrhiza uralensis) 및 노랑민들레(Taraxacum officinale) 추출물의 혼합물을 유효성분으로 함유하는 알코올성 위장관질환의 예방 또는 개선용 건강기능식품 조성물을 제공한다.In addition, the present invention is licorice ( Glycyrrhiza uralensis ) and yellow dandelion ( Taraxacum) officinale) provides a mixture of an alcoholic gastrointestinal disease preventing or improving functional health food composition for containing, as an active ingredient of the extract.
감초는 감초속(Glycyrrhiza)에 속하는 다년생 초본식물을 의미하며, 본 발명에서 사용된 감초는 농촌진흥청에서 개발한 ‘원감 (Glycyrrhiza uralensis)’으로, 만주 감초(Glycyrrhiza uralensis Fische)와 유럽 감초 (Glycyrrhiza glabra Linne)의 기능성을 보완한 새 품종이다. 원감은 만주 감초보다 줄기가 곧고 쓰러짐에 강하며 뿌리수가 많아 수확량도 만주 감초보다 높은 특징이 있다.Licorice means a perennial herbaceous plant belonging to the genus Licorice (Glycyrrhiza), the licorice used in the present invention is ' Glycyrrhiza ' developed by the Rural Development Administration uralensis ', Glycyrrhiza uralensis Fische) and European licorice ( Glycyrrhiza glabra Linne) is a new breed that complements the functionality. The persimmon has a higher stem and a stronger root than Manchurian licorice, and the yield is higher than that of Manchurian licorice.
민들레는 속씨식물문의 쌍자엽강에 속하는 다년생 초본 식물로, 안질방이, 무슨들레라고도 불린다. 꽃은 4-5월에 피며, 예로부터 어린 잎은 나물과 국거리로 식용해 왔다 (김일혁 및 성환길, 약이 되는 풀과 나무, 중앙대학교 출판부, p332, 1997). 또한, 민들레는 꽃이 피기 전에 전초를 건조한 것을 포공영 (김원, 자원식물학, 경북대학교 출판부, p190, 1987)이라 하며 한방에서는 강장, 해열, 이뇨, 건위, 거담, 해독 등에 이용되어 왔다 (홍석화, 한국의 토종 101가지, 웅진출판사, 1990, 18). 민들레의 맛과 성질은 쓰고 달며, 차갑다. 전초는 이담 작용이 있으며 위액의 분비를 빠르게 한다. 본 발명에서는 노랑민들레(Taraxacum officinale)를 사용하였다.Dandelion is a perennial herbaceous plant belonging to the dicotyledonous genus of the genus Botanical Gate. Flowers bloom in April-May, and young leaves have been edible with herbs and national streets (Kim Il-hyuk and Seonghwan-gil, medicinal grasses and trees, Chung-Ang University Press, p332, 1997). Dandelion is also called pogongyoung (Kim Won, Botanical Botany, Kyungpook National University Press, p190, 1987). 101 native species, Woongjin Press, 1990, 18). Dandelion taste and properties are bitter and sweet. Outpost has an edema and speeds up the secretion of gastric juice. In the present invention, yellow dandelion ( Taraxacum officinale ) was used.
상기 감초 추출물 및 노랑민들레 추출물은 다양한 기관 또는 부분(예를 들어, 잎, 꽃, 뿌리, 줄기, 가지, 껍질 및 종자 등)으로부터 추출하여 얻을 수 있다. 본 발명에서 감초 추출물은 감초의 뿌리 부위를 원료로 하여 제조하는 것이 바람직하고, 노랑민들레 추출물은 노랑민들레의 지상부를 원료로 하여 제조하는 것이 바람직하다. 상기 용어 “지상부”는 꽃과 뿌리를 제거한 잎과 줄기 부위를 의미한다.The licorice extract and yellow dandelion extract can be obtained by extracting from various organs or parts (for example, leaves, flowers, roots, stems, branches, shells and seeds, etc.). Licorice extract in the present invention is preferably prepared by using the root portion of licorice, yellow dandelion extract is preferably prepared by using the ground portion of the yellow dandelion. The term "ground" refers to the leaf and stem area from which flowers and roots are removed.
본 발명의 용어 "추출물"은 상기 감초 또는 노랑민들레의 추출처리에 의하여 얻어지는 추출액, 상기 추출액의 희석액이나 농충액, 상기 추출액을 건조하여 얻어지는 건조물, 상기 추출액의 조정제물이나 정제물, 또는 이들의 혼합물 등, 추출액 자체 및 추출액을 이용하여 형성 가능한 모든 제형의 추출물을 포함한다. 구체적으로 본 발명의 상기 추출물은 추출 후 건조 분말 형태로 제조되어 사용될 수 있다.The term " extract " of the present invention refers to an extract obtained by extracting licorice or yellow dandelion, a diluent or pesticide solution of the extract, a dried product obtained by drying the extract, a crude or purified product of the extract, or a mixture thereof. And the like, and extracts of all formulations that can be formed using the extract itself and the extract. Specifically, the extract of the present invention may be prepared and used in the form of a dry powder after extraction.
본 발명의 상기 추출물은, 상기 식물의 천연, 잡종 또는 변종 식물로부터 추출될 수 있고, 식물 조직 배양물로부터도 추출이 가능하다.The extract of the present invention can be extracted from natural, hybrid or variety plants of the plant, it is also possible to extract from plant tissue culture.
본 발명의 상기 감초 또는 노랑민들레의 추출에 있어서, 상기 추출하는 방법은 특별히 제한되지 아니하며, 당해 기술분야에서 통상적으로 사용하는 방법에 따라 추출할 수 있다. 상기 추출 방법의 비제한적인 예로는, 열수 추출법, 초음파 추출법, 여과법, 환류 추출법 등을 들 수 있으며, 이들은 단독으로 수행되거나 2 종 이상의 방법을 병용하여 수행될 수 있다.In the extraction of the licorice or yellow dandelion of the present invention, the extraction method is not particularly limited and may be extracted according to a method commonly used in the art. Non-limiting examples of the extraction method, hot water extraction method, ultrasonic extraction method, filtration method, reflux extraction method and the like, these may be carried out alone or in combination of two or more methods.
본 발명에서 상기 감초 또는 노랑민들레를 추출하는 데 사용되는 추출 용매의 종류는 특별히 제한되지 아니하며, 당해기술 분야에서 공지된 임의의 용매를 사용할 수 있다. 상기 추출 용매의 비제한적인 예로는 물; 메탄올, 에탄올, 프로필알코올, 부틸알코올 등의 C1~C4의 저급 알코올; 글리세린, 부틸렌글리콜, 프로필렌글리콜 등의 다가 알코올; 및 메틸아세테이트, 에틸아세테이트, 아세톤, 벤젠, 헥산, 디에틸에테르, 디클로로메탄 등의 탄화수소계 용매; 또는 이들의 혼합물을 사용할 수 있으며, 구체적으로는 상기 감초 또는 노랑민들레를 물, C1~C4의 알코올 또는 이들의 혼합용매로 추출할 수 있으나, 이에 제한되는 것은 아니다. 본 발명에서 상기 저급 알코올은 에탄올일 수 있으나, 이에 제한되는 것은 아니다.The kind of the extraction solvent used to extract the licorice or yellow dandelion in the present invention is not particularly limited, and any solvent known in the art may be used. Non-limiting examples of such extraction solvents include water; Lower alcohols such as C 1 to C 4 such as methanol, ethanol, propyl alcohol and butyl alcohol; Polyhydric alcohols such as glycerin, butylene glycol, and propylene glycol; Hydrocarbon solvents such as methyl acetate, ethyl acetate, acetone, benzene, hexane, diethyl ether and dichloromethane; Or a mixture thereof may be used, and specifically, the licorice or yellow dandelion may be extracted with water, C 1 to C 4 alcohol or a mixed solvent thereof, but is not limited thereto. In the present invention, the lower alcohol may be ethanol, but is not limited thereto.
본 발명의 일실시예에서는 세척 및 건조로 이물질이 제거된 감초 뿌리와 노랑민들레 지상부를 동결건조한 후 분쇄하여 물로 3회 반복하여 열수 추출하였다. 필요한 경우에는 당업계에 공지된 방법에 따라 여과, 농축 및 동결건조 등의 단계를 추가적으로 거쳐 분말로 제조될 수 있다.In one embodiment of the present invention, the licorice root and yellow dandelion ground portion from which foreign substances were removed by washing and drying were lyophilized, pulverized, and extracted with hot water three times. If necessary, it may be prepared as a powder through additional steps such as filtration, concentration and lyophilization according to methods known in the art.
본 발명의 일실시예에서는, 본 발명의 감초와 노랑민들레 추출물의 혼합물을 함유하는 조성물의 알코올성 위염 개선 효과를 확인하기 위해 알코올, 바람직하게는 에탄올 투여로 위 염증이 발생한 래트 동물모델에서 위 조직의 조직병리학적 평가 및 염증 발생 면적을 분석하였다.In one embodiment of the present invention, in order to confirm the alcoholic gastritis improvement effect of the composition containing the mixture of licorice and yellow dandelion extract of the present invention of the gastric tissue in a rat animal model in which the gastric inflammation occurred by administration of alcohol, preferably ethanol Histopathological evaluation and inflammation incidence area were analyzed.
도 1 및 2에 나타난 바와 같이, 에탄올만 투여한 대조군의 경우 위 조직의 염증, 출혈, 발적 및 부종이 발생하였고, 손상 부위 면적 또한 매우 넓었다. 단독 추출물 투여의 경우, 노랑민들레 추출물의 위 조직 염증 개선효과가 감초 추출물보다 우수하였다. 상기 단독 추출물 투여군과 동일한 양으로 투여하되 중량비를 달리하여 혼합한 혼합물 A, B 및 C를 각각 투여한 실험군에서는 특정 중량비에서 특이적인 상승효과가 나타남을 확인하였다.As shown in Figures 1 and 2, the control group administered only with ethanol, inflammation, bleeding, redness and edema of the gastric tissue occurred, the damage area was also very large. In the case of the administration of the extract alone, yellow dandelion extract showed better gastric tissue inflammation than the licorice extract. It was confirmed that a specific synergistic effect was observed at a specific weight ratio in the experimental group administered with the mixture A, B and C, respectively, which were administered in the same amount as the single extract administration group but mixed in different weight ratios.
구체적으로, 혼합물에서 노랑민들레 추출물의 중량비가 증가할수록 복합 상승효과가 증가되었다. 바람직한 혼합 중량비는 1:0.25 내지 1:4이고, 더욱 바람직하게는 1:1 내지 1:4이며, 가장 바람직한 혼합 중량비는 1:4일 수 있다. 특히, 감초 추출물과 노랑민들레 추출물의 혼합 중량비가 1:1 내지 1:4인 경우, 감초 추출물 또는 노랑민들레 추출물의 단독 투여군에서 나타난 위 조직 염증 개선 효과보다 뛰어난 효과를 나타내어 혼합에 따른 최대의 복합 상승효과가 나타남을 확인하였다. Specifically, the composite synergy was increased as the weight ratio of the yellow dandelion extract in the mixture increased. Preferred mixing weight ratios are 1: 0.25 to 1: 4, more preferably 1: 1 to 1: 4, and the most preferred mixing weight ratio may be 1: 4. In particular, when the mixed weight ratio of licorice extract and yellow dandelion extract is 1: 1 to 1: 4, it shows a superior effect to gastric tissue inflammation improvement effect in the administration group of licorice extract or yellow dandelion extract, so that the maximum complex elevation by mixing It was confirmed that the effect appeared.
감초와 노랑민들레 추출물을 상기 범위를 벗어난 중량비로 혼합할 경우, 두 가지 추출물의 복합 상승효과가 감소하여 최적의 활성을 나타낼 수 없으므로(도 1 및 2), 상기 중량비 범위 내에서 두 가지 추출물을 혼합하는 것이 바람직하다.When licorice and yellow dandelion extract is mixed in a weight ratio outside the above range, the composite synergy of the two extracts is reduced to show the optimal activity (Figs. 1 and 2), so the two extracts are mixed within the weight ratio range. It is desirable to.
또한, 도3에 나타난 바와 같이 혼합물 A, B 및 C를 각각 투여한 실험군 중 혼합물 B 및 C 투여군에서 iNOS의 발현이 현저하게 억제됨을 확인하였고, 특히 감초 추출물과 노랑민들레 추출물이 1:4의 중량비로 혼합된 혼합물 C군에서 iNOS 발현 억제 효과가 최대로 나타남을 확인하였다.In addition, as shown in FIG. 3, it was confirmed that iNOS expression was significantly suppressed in the mixture B and C administration groups among the experimental groups to which the mixtures A, B and C were administered, in particular, the licorice extract and the yellow dandelion extract had a weight ratio of 1: 4. It was confirmed that the maximum iNOS expression inhibitory effect in the mixture C group mixed with.
따라서, 감초 추출물과 노랑민들레 추출물을 1:1 내지 1:4의 중량비로 혼합한 혼합물은 알코올로 유발된 위 조직의 염증을 현저하게 완화시켜 알코올성 위염 치료에 탁월한 효능이 있음을 알 수 있다.Therefore, it can be seen that the mixture of licorice extract and yellow dandelion extract in a weight ratio of 1: 1 to 1: 4 remarkably alleviates the inflammation of alcohol-induced gastric tissues and has excellent efficacy in treating alcoholic gastritis.
본 발명에 있어서, “알코올성 위장관질환”은 알코올에 의한 위 손상으로 유발되는 모든 질환을 의마한다. 예를 들어, 알코올에 의해 유도된 급성 위점막 손상, 위궤양, 급성 위염 및 만성 위염으로 이루어진 군으로부터 선택한 1종 이상일 수 있으나, 이에 제한되는 것은 아니다.In the present invention, "alcoholic gastrointestinal disease" refers to any disease caused by gastric injury by alcohol. For example, it may be one or more selected from the group consisting of alcohol-induced acute gastric mucosal injury, gastric ulcer, acute gastritis and chronic gastritis, but is not limited thereto.
추가로, 본 발명의 감초 추출물 및 노랑민들레 추출물의 혼합물은 알코올성 간 손상에 대한 예방 효과를 나타낼 수 있다. In addition, the mixture of licorice extract and yellow dandelion extract of the present invention may exhibit a protective effect against alcoholic liver damage.
간과 관련된 여러 질환들을 감별하기 위해서는 몇 가지 화학적 검사들을 종합적으로 해석하는 것이 필요한데, 이를 위하여 몇 가지 검사항목들을 묶어 간 기능 검사로 통칭한다. 주요 검사로는 GOT, GPT 등이 있고, 이외에도 총 단백질, 알부민, 암모니아 등의 항목을 더하여 검사하는 경우도 많다.In order to distinguish the various diseases related to the liver, it is necessary to interpret several chemical tests comprehensively. For this purpose, several test items are collectively referred to as liver function tests. Major tests include GOT, GPT, etc. In addition, many tests are performed by adding items such as total protein, albumin, and ammonia.
GOT(glutamic oxaloacetic transaminase, 아스파르트산 아미노기전달효소)는 L-아스파르트산의 아미노기를 α-케토글루타르산으로 전달하여 옥살로아세트산과 L-글루탐산을 생성하는 가역반응을 촉매하는 효소이다. 간염, 심근경색 등의 진단 시 혈중에서의 이 효소 활성에 대한 측정이 자주 이용된다.GOT (glutamic oxaloacetic transaminase) is an enzyme that catalyzes the reversible reaction of oxaloacetic acid and L-glutamic acid by transferring the amino group of L-aspartic acid to α-ketoglutaric acid. Measurements of this enzyme activity in the blood are frequently used in the diagnosis of hepatitis and myocardial infarction.
GPT(glutamic-pyruvic transaminase, 알라닌 아미노기전달효소)는 알라닌의 아미노기를 α-케토글루타르산에 전달하여 피루브산과 글루탐산 생성반응을 촉매하는 효소이다. 간·담도계 질환의 진단을 위해 혈액 중의 이 효소의 활성 측정이 자주 이루어진다.GPT (glutamic-pyruvic transaminase, alanine aminotransferase) is an enzyme that catalyzes the production of pyruvic acid and glutamic acid by transferring the amino group of alanine to α-ketoglutaric acid. The activity of this enzyme in the blood is often measured for the diagnosis of liver and biliary tract diseases.
따라서, 본 발명에서는 알코올성 간 손상에 대한 개선 효과를 GOT 및 GPT 수치 측정을 통해 확인하였다. 도 4에 나타난 바와 같이, 본 발명의 감초 추출물 및 노랑민들레 추출물의 혼합물을 함유하는 조성물은 알코올, 바람직하게는 에탄올 투여로 증가된 GOT 및 GPT 수치를 현저하게 감소시킴을 확인하였다. 혼합물 투여군의 현저한 상승효과는 투여된 혼합물이 에탄올 보다 빠르게 흡수되어 GOT 및 GPT 수치를 감소시키기 때문에 나타나는 것으로 판단된다.Therefore, in the present invention, the improvement effect on alcoholic liver damage was confirmed by measuring GOT and GPT levels. As shown in Figure 4, the composition containing the mixture of licorice extract and yellow dandelion extract of the present invention was found to significantly reduce the GOT and GPT levels increased by the administration of alcohol, preferably ethanol. The significant synergistic effect of the mixture administration group is believed to be due to the fact that the administered mixture is absorbed faster than ethanol to reduce GOT and GPT levels.
이상의 결과를 통해, 본 발명의 감초 추출물 및 노랑민들레 추출물의 혼합물은 알코올에 의한 위 손상 개선뿐만 아니라 간 손상 예방 효과를 나타내어 알코올의 과다 섭취로부터 위와 간을 동시에 보호할 수 있음을 알 수 있다.Through the above results, it can be seen that the mixture of licorice extract and yellow dandelion extract of the present invention not only improves gastric damage by alcohol but also prevents liver damage, thereby protecting stomach and liver from excessive intake of alcohol at the same time.
본 발명의 약학적 조성물은 약학적 조성물의 제조에 통상적으로 사용하는 적절한 담체, 부형제 및 희석제를 더 포함할 수 있다.The pharmaceutical compositions of the present invention may further comprise suitable carriers, excipients and diluents commonly used in the manufacture of pharmaceutical compositions.
본 발명에 따른 약학적 조성물은, 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있다.The pharmaceutical compositions according to the present invention may be formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like, oral preparations, suppositories, and sterile injectable solutions, respectively, according to conventional methods. Can be used.
본 발명의 조성물에 함유될 수 있는 담체, 부형제 및 희석제로는 락토오즈(lactose), 덱스트로즈, 수크로스(sucrose), 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다.Carriers, excipients and diluents that may be included in the compositions of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin , Calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다.When formulated, diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, and surfactants are usually used.
경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 상기 화합물에 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘카보네이트(calcium carbonate), 수크로스 또는 락토오스, 젤라틴 등을 섞어 조제된다. 또한 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용된다. 경구를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순 희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다.Solid form preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, which form at least one excipient such as starch, calcium carbonate, sucrose or lactose in the compound. Mixed with gelatin. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Oral liquid preparations include suspensions, solvents, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. .
비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제가 포함된다. 비수성용제, 현탁제로는 프로필렌글리콜(propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다.Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories. As the non-aqueous solvent and suspending agent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate and the like can be used. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
상기 본 발명의 약학적 조성물은 약제학적으로 유효한 양으로 투여한다.The pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount.
본 발명에서 용어 "약제학적으로 유효한 양"은 의학적 치료에 적용 가능한 합리적인 수혜/위험 비율로 질환을 치료하기에 충분한 양을 의미하며, 유효 용량 수준은 개체 종류 및 중증도, 연령, 성별, 감염된 바이러스 종류, 약물의 활성, 약물에 대한 민감도, 투여 시간, 투여 경로 및 배출 비율, 치료기간, 동시 사용되는 약물을 포함한 요소 및 기타 의학 분야에 잘 알려진 요소에 따라 결정될 수 있다. 본 발명의 조성물은 개별 치료제로 투여하거나 다른 치료제와 병용하여 투여될 수 있고 종래의 치료제와는 순차적 또는 동시에 투여될 수 있다. 그리고 단일 또는 다중 투여될 수 있다. 상기 요소를 모두 고려하여 부작용없이 최소한의 양으로 최대 효과를 얻을 수 있는 양을 투여하는 것이 중요하며, 당업자에 의해 용이하게 결정될 수 있다.As used herein, the term "pharmaceutically effective amount" refers to an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and the effective dose level refers to the individual type and severity, age, sex, type of virus infected. , The activity of the drug, the sensitivity to the drug, the time of administration, the route of administration and the rate of release, the duration of treatment, factors including the concurrent drug and other factors well known in the medical field. The compositions of the present invention may be administered as individual therapeutic agents or in combination with other therapeutic agents and may be administered sequentially or simultaneously with conventional therapeutic agents. And single or multiple administrations. Taking all of the above factors into consideration, it is important to administer an amount that can obtain the maximum effect in a minimum amount without side effects, and can be easily determined by those skilled in the art.
본 발명의 약학적 조성물은 단독으로, 또는 수술, 호르몬 치료, 약물 치료 및 생물학적 반응 조절제를 사용하는 방법들과 병용하여 사용할 수 있다.The pharmaceutical compositions of the present invention may be used alone or in combination with methods using surgery, hormone therapy, drug therapy and biological response modifiers.
상기 조성물은 쥐, 생쥐, 가축, 인간 등의 포유동물에 다양한 경로로 투여될 수 있다. 투여의 모든 방식은 예상될 수 있는데, 예를 들면, 경구, 직장 또는 정맥, 근육, 피하, 자궁 내 경막 또는 뇌혈관 내 주사에 의해 투여될 수 있다.The composition can be administered to mammals such as mice, mice, livestock, humans, and the like by various routes. All modes of administration can be expected, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine dural or cerebrovascular injections.
본 발명의 감초 추출물과 노랑민들레 추출물의 혼합물을 식품 첨가물로 사용할 경우, 상기 혼합물을 그대로 첨가하거나 다른 식품 또는 식품 성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다. 유효성분의 혼합량은 사용 목적 (예방, 건강 또는 치료적 처치)에 따라 적합하게 결정될 수 있다. 일반적으로, 식품 또는 음료의 제조 시에는 본 발명의 조성물은 원료에 대하여 0.01 ~ 10 중량%, 바람직하게는 0.05 ~ 1 중량%의 양으로 첨가된다. 그러나 건강 및 위생을 목적으로 하거나 또는 건강 조절을 목적으로 하는 장기간의 섭취의 경우에는 상기 양은 상기 범위 이하로도 사용될 수 있다.When the mixture of licorice extract and yellow dandelion extract of the present invention is used as a food additive, the mixture can be added as it is or used with other food or food ingredients, and can be appropriately used according to a conventional method. The mixed amount of the active ingredient may be appropriately determined depending on the purpose of use (prevention, health or therapeutic treatment). In general, in the manufacture of food or beverages, the composition of the present invention is added in an amount of 0.01 to 10% by weight, preferably 0.05 to 1% by weight based on the raw materials. However, in the case of prolonged ingestion for health and hygiene purposes or for health control purposes, the amount may be used below the above range.
상기 건강기능식품은 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산음료에 사용되는 탄산화제 등을 함유할 수 있다. 그 밖에 천연 과일 주스 및 과일 주스 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 또한, 건강기능식품은 육류, 소세지, 빵, 초콜릿, 캔디류, 스넥류, 과자류, 피자, 라면, 껌류, 아이스크림류, 스프, 음료수, 차, 기능수, 드링크제, 알코올 및 비타민 복합제 중 어느 하나의 형태일 수 있다.The health functional food includes various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, coloring and neutralizing agents (such as cheese and chocolate), pectic acid and salts thereof, alginic acid and salts thereof, Organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated drinks and the like. It may also contain natural fruit juices and pulp for the production of fruit juices and vegetable drinks. These components can be used independently or in combination. The dietary supplement may be any one of meat, sausage, bread, chocolate, candy, snacks, confectionary, pizza, ramen, gum, ice cream, soup, beverage, tea, functional water, drink, alcohol and vitamin complex. Can be.
본 발명의 건강 음료 조성물은 감초 추출물과 노랑민들레 추출물의 혼합물을 함유하는 것 외에는 액체성분에는 특별한 제한은 없으며 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다.The health beverage composition of the present invention is not particularly limited in liquid components except for containing a mixture of licorice extract and yellow dandelion extract, and may contain various flavors or natural carbohydrates as additional ingredients, such as ordinary drinks.
또한, 상기 건강기능식품은 식품첨가물을 추가로 포함할 수 있으며, “식품첨가물”로서의 적합여부는 다른 규정이 없는 한 식품의약품안정청에 승인된 식품첨가물공전의 총칙 및 일반시험법 등에 따라 해당 품목에 관한 규격 및 기준에 의하여 판정한다.In addition, the health functional food may further include food additives, and the suitability as a "food additive" to the item in accordance with the General Regulations of the Food Additives Code and General Test Act, etc. approved by the Food and Drug Administration unless otherwise specified. Determined by the relevant standards and standards.
상기 “식품첨가물공전”에 수재된 품목으로 예를 들어, 케톤류, 글리신, 구연산 칼륨, 니코틴산, 계피산 등의 화학적 합성품, 감색소, 감초추출물, 결정셀룰로오스, 고랭색소, 구아검 등의 천연첨가물, L-글루타민산나트륨제제, 면류첨가알칼리제, 보존료제제, 타르색소제제 등의 혼합 제제류 등을 들 수 있다.Items listed in the "Food Additives Code" include, for example, chemical synthetic products such as ketones, glycine, potassium citrate, nicotinic acid, cinnamic acid, natural additives such as color pigments, licorice extract, crystalline cellulose, high-quench pigments, guar gum, L Mixed preparations, such as a sodium glutamate preparation, a noodles addition alkali preparation, a preservative preparation, and a tar pigment preparation, etc. are mentioned.
하기의 실시예를 통하여 본 발명을 더욱 구체적으로 설명하기로 하지만, 하기의 실시예가 본 발명의 범위를 제한하는 것은 아니며, 이는 본 발명의 이해를 돕기 위한 것으로 해석되어야 할 것이다.Although the present invention will be described in more detail with reference to the following examples, the following examples are not intended to limit the scope of the present invention, which will be construed as to aid the understanding of the present invention.
1-1. 감초 뿌리 추출물 및 노랑민들레 지상부 추출물의 제조1-1. Preparation of Licorice Root Extract and Yellow Dandelion Ground Extract
수확한 감초의 뿌리와 노랑민들레의 지상부를 물로 세척하고 동결건조기(Martin Christ, Osterode, Germany)로 동결건조하였다. 동결건조된 시료를 분쇄 후 각각의 시료 150g에 물 1,000ml를 첨가하여 3시간, 3회 반복하여 열수추출하였다. 추출물은 와트만 (Whatman 46cm) 여과지를 이용하여 불용성 물질을 제거하고, 여과된 추출물은 회전감압농축기(Heidolph, Germanay)로 60℃에서 감압농축하였다. 감압농축된 추출물의 용매를 완전히 제거하기 위하여 정제수 50 ml를 넣어 현탁시킨 후 동결건조기를 이용하여 감초 뿌리 추출 동결건조물 27.5g과 노랑민들레 지상부 추출 동결건조물 61.3g을 수득하였다 (감초 추출물 수율: 18.3%, 노랑민들레 추출물 수율: 40.9%).The roots of the harvested licorice and the tops of yellow dandelions were washed with water and lyophilized with a lyophilizer (Martin Christ, Osterode, Germany). The lyophilized samples were milled, and 1,000 ml of water was added to 150 g of each sample, followed by repeated extraction of hot water three times for three hours. The extract was removed by using a Whatman 46 cm filter paper, insoluble matters, and the filtered extract was concentrated under reduced pressure at 60 ℃ with a Heidolph, Germanay. In order to completely remove the solvent of the extract under reduced pressure, 50 ml of purified water was added and suspended, and then 27.5 g of licorice root extract lyophilisate and 61.3 g of yellow dandelion ground extract lyophilized were obtained using a freeze dryer (Licorice extract yield: 18.3%). , Yellow dandelion extract yield: 40.9%).
1-2. 실험 동물1-2. Experimental animals
7주령 된 Spraque-Dawley 수컷 래트를 (주)오리엔트바이오로부터 구입하였다. 22℃에서 명/암 주기를 12시간 간격으로 설정하고, 식이와 물을 자유롭게 공급하여 1 주일간 기본식이로 적응시켰다.Seven-week-old Spraque-Dawley male rats were purchased from Orient Bio. The light / dark cycle was set at 12 ° C at 12 hour intervals, and the diet and water were freely adapted to the basic diet for 1 week.
알코올성 위염 개선 효과의 확인Confirmation of alcoholic gastritis improvement effect
2-1. 실험군 설정 및 시료 투여2-1. Experiment set and sample administration
상기 실시예 1-2의 실험동물을 각 군당 5마리씩, 아무것도 처리하지 않은 정상군, 5.0g/kg의 에탄올만을 투여한 대조군, 위염치료제로 사용중인 레바미피드(rebamipide)를 5.0g/kg의 에탄올에 용해하여 투여한 양성대조군 및 5.0g/kg의 에탄올에 용해된 각각의 실험시료를 투여한 5개의 실험군으로 나누어 실험을 진행하였다. 5개의 실험군에 대해 투여된 실험시료의 정보는 하기 표 1에 기재된 바와 같다. Each of the experimental animals of Example 1-2, 5 mice in each group, the normal group untreated, 5.0 g / kg control group administered only, 5.0 g / kg of rebamipide in use as a gastritis treatment The experiment was conducted by dividing into a positive control group dissolved in ethanol and five test groups administered each test sample dissolved in 5.0 g / kg of ethanol. Information of the test samples administered for the five test groups is as described in Table 1 below.
실험동물을 12시간 절식시킨 후 실험시료를 에탄올(5.0g/kg)로 용해하여 1회 경구투여하고, 1시간 후에 에테르 마취하여 개복 후 심장 채혈 및 위 조직을 적출하였다.After the animal was fasted for 12 hours, the test sample was dissolved in ethanol (5.0 g / kg) and orally administered once, and after 1 hour, ether anesthesia was used to remove heart blood and stomach tissues after laparotomy.
지상부 추출물Yellow dandelion
Ground
2-2. 위 조직의 조직병리학적 평가 및 염증 발생 면적 분석2-2. Histopathological evaluation and inflammation area analysis of gastric tissue
각 군에서 적출한 위 조직을 고정하여 손상된 범위 및 손상 정도를 관찰하였다. 그 결과, 도 1에 나타난 바와 같이 에탄올만 투여한 대조군의 경우, 위 조직의 염증, 출혈, 발적 및 부종이 발생하였고 손상 부위 면적 또한 매우 넓었다. 이러한 위 조직 손상은 혼합물 B 및 C 투여군에서 눈에 띄게 회복되었다.The stomach tissues extracted from each group were fixed to observe the extent of damage and extent of damage. As a result, as shown in Figure 1, the control group administered only with ethanol, inflammation, bleeding, redness and edema of the gastric tissue occurred and the damage area was also very large. This gastric tissue injury was remarkably recovered in the mixture B and C administration groups.
적출한 위 조직의 염증 발생 면적을 백분율로 환산하여 계산한 결과, 도 2에 나타난 바와 같이 감초 투여군 및 노랑민들레 투여군의 염증 발생 면적은 각각 43.3% 및 31.0%였고, 혼합물 A 투여군, 혼합물 B 투여군 및 혼합물 C 투여군의 염증 발생 면적은 41.9% 및 29.6% 및 20.2%였다.As shown in FIG. 2, the area of inflammation occurrence of the licorice group and the yellow dandelion group was 43.3% and 31.0%, respectively, and the mixture A administration group, the mixture B administration group, and Inflammation area of the mixture C administration group was 41.9% and 29.6% and 20.2%.
이를 통해, 다른 실험군들에 비해 감초 뿌리 추출물과 노랑민들레 지상부 추출물이 1:4의 중량비로 혼합된 혼합물 C군에서 상승 효과가 최대로 나타나 위 조직 손상이 현저하게 완화됨을 확인하였다.As a result, the synergistic effect was maximized in the mixture C group in which the licorice root extract and the yellow dandelion ground extract were mixed at a weight ratio of 1: 4, compared to other experimental groups, and it was confirmed that gastric tissue damage was remarkably alleviated.
2-3. 위 조직의 염증관련 단백질의 발현 억제 효과 확인2-3. Confirmation of Inhibitory Effect of Inflammation-Related Proteins
감초 뿌리 추출물과 노랑민들레 지상부 추출물의 혼합물 투여에 의한 염증 관련 단백질(iNOS)의 발현 변화를 평가하기 위해 웨스턴 블롯(Western blot) 실험방법으로 단백질량을 측정하여 확인하였다.In order to evaluate the change in the expression of inflammation-related protein (iNOS) by the administration of a mixture of licorice root extract and yellow dandelion ground extract, it was confirmed by measuring the amount of protein by Western blot test method.
10 ㎍의 단백질을 SDS-폴리아크릴아미드 겔을 이용하여 전기영동으로 분리한 후, 아크릴아미드 겔을 니트로셀룰로오스 멤브래인으로 옮겼다. 그 다음 5% 스킴 밀크(skim milk)를 함유한 TBS-T (TBS에 용해된 0.5% 트윈 20)에 담구어 1시간 처리한 후 TBS-T로 5분마다 5회 세척하였다. 준비된 멤브래인에 1차 항체를 처리하여 4℃에서 하룻밤 동안 둔 다음 TBS-T로 10분마다 5회 세척하였다. 처리된 1차 항체에 맞는 2차 항체 (TBS-T로 1:5000로 희석해서 사용)를 사용하여 상온에서 1시간 30분 반응시킨 후, TBS-T로 10분마다 5회 세척하였다. ECL 용액으로 반응시킨 후 Davinch-ChemiTM Chemiluminescence Imaging system (Davinch-K Co., Ltd., 서울, 대한민국)에 감광시켜 단백질 발현을 확인한 다음, 해당 밴드를 ATTO Densitograph Software (ATTO Corporation, Tokyo, Japan) 프로그램을 사용하여 정량하였다.After 10 μg of protein was electrophoretically separated using SDS-polyacrylamide gel, the acrylamide gel was transferred to nitrocellulose membrane. Then, it was immersed in TBS-T (0.5
그 결과, 도 3에 나타난 바와 같이 실험군 중 혼합물 B 및 C 투여군에서 iNOS의 발현이 현저하게 억제됨을 확인하였고, 특히 감초 뿌리 추출물과 노랑민들레 지상부 추출물이 1:4의 중량비로 혼합된 혼합물 C군에서 iNOS 발현 억제 효과가 최대로 나타남을 확인하였다.As a result, as shown in FIG. 3, it was confirmed that iNOS expression was significantly suppressed in the mixtures B and C administration group of the experimental group, especially in the mixture C group in which licorice root extract and yellow dandelion ground extract were mixed in a weight ratio of 1: 4. It was confirmed that the iNOS expression inhibitory effect appeared to the maximum.
상기 결과를 통해 감초 뿌리 추출물과 노랑민들레 지상부 추출물이 1:1 내지 1:4의 중량비로 혼합된 조성물이 알코올성 위염을 치료하는데 매우 유용함을 확인하였다.The results confirm that the licorice root extract and the yellow dandelion extract above ground extract in a weight ratio of 1: 1 to 1: 4 is very useful for the treatment of alcoholic gastritis.
혈청 중 간 기능 지표효소 활성 측정Determination of liver function marker enzyme activity in serum
상기 실시예 2-1의 실험동물로부터 채혈한 혈액에서 GOT (glutamic oxaloacetic transaminase) 및 GPT (glutamic-pyruvic transaminase) 활성을 제조사의 지시에 따라 진단 키트(Procedure No. 505, Sigma Chemical Co., St Louis, MO)를 사용하여 비색법으로(colorimetrically) 측정하였다.GOT (glutamic oxaloacetic transaminase) and GPT (glutamic-pyruvic transaminase) activity in the blood collected from the experimental animals of Example 2-1 according to the manufacturer's instructions diagnostic kit (Procedure No. 505, Sigma Chemical Co., St Louis , MO) was measured colorimetrically.
그 결과, 도 4에 나타난 바와 같이 에탄올 투여로 GOT 및 GPT 수치가 증가하였고(대조군), 혼합물 A군, B군 및 C군은 감초 및 노랑민들레를 각각 단독으로 투여한 군보다 GOT 및 GPT 수치가 현저하게 감소됨을 확인하였다. 혼합물 투여군의 현저한 상승효과는 투여된 혼합물이 에탄올 보다 빠르게 흡수되어 GOT 및 GPT 수치를 감소시키기 때문에 나타나는 것으로 판단되며, 이를 통해 본 발명의 감초 뿌리 추출물 및 노랑민들레 지상부 추출물의 혼합물은 알코올에 의한 간 손상을 효과적으로 예방할 수 있음을 알 수 있다.As a result, as shown in FIG. 4, the GOT and GPT levels were increased by ethanol administration (control group), and the mixture A, B, and C groups showed higher GOT and GPT levels than the licorice and yellow dandelions alone. It was found to be significantly reduced. Significant synergistic effect of the mixture administration group appears to be because the mixture is absorbed faster than ethanol to reduce GOT and GPT levels, through which the mixture of licorice root extract and yellow dandelion ground extract of the present invention is damaged by alcohol It can be seen that can effectively prevent.
제조예 1: 약학적 제제의 제조Preparation Example 1 Preparation of Pharmaceutical Formulation
1-1. 산제의 제조1-1. Manufacture of powder
감초 뿌리 추출물 0.5g과 노랑민들레 지상부 추출물 2.0g의 혼합물 또는 감초 뿌리 추출물 1.25g과 노랑민들레 지상부 추출물 1.25g의 혼합물을 유당 1g과 혼합한 후, 기밀포에 충진하여 산제를 제조하였다.A mixture of 0.5 g of licorice root extract and 2.0 g of yellow dandelion ground extract or 1.25 g of licorice root extract and 1.25 g of yellow dandelion ground extract was mixed with 1 g of lactose and filled with an airtight cloth to prepare a powder.
1-2. 정제의 제조1-2. Manufacture of tablets
감초 뿌리 추출물 25mg과 노랑민들레 지상부 추출물 100mg의 혼합물 또는 감초 뿌리 추출물 62.5mg과 노랑민들레 지상부 추출물 62.5mg의 혼합물을 옥수수 전분 100 ㎎, 유당 100 ㎎ 및 스테아린산 마그네슘 2 ㎎과 혼합한 후, 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조하였다.A mixture of 25 mg of licorice root extract and 100 mg of yellow dandelion ground extract or a mixture of 62.5 mg of licorice root extract and 62.5 mg of yellow dandelion ground extract is mixed with 100 mg of corn starch, 100 mg of lactose and 2 mg of magnesium stearate. Tablets were prepared by tableting according to the preparation method.
1-3. 캡슐제의 제조1-3. Preparation of Capsule
감초 뿌리 추출물 0.5g과 노랑민들레 지상부 추출물 2.0g의 혼합물 또는 감초 뿌리 추출물 1.25g과 노랑민들레 지상부 추출물 1.25g의 혼합물을 옥수수 전분 100 ㎎, 유당 100 ㎎ 및 스테아린산 마그네슘 2 ㎎과 혼합한 후, 통상의 캡슐제의 제조방법에 따라서 젤라틴 캡슐에 충전하여 캡슐제를 제조하였다.A mixture of 0.5 g of licorice root extract and 2.0 g of yellow dandelion ground extract or 1.25 g of licorice root extract and 1.25 g of yellow dandelion ground extract was mixed with 100 mg of corn starch, 100 mg of lactose and 2 mg of magnesium stearate. The capsule was prepared by filling the gelatin capsule according to the preparation method of the capsule.
1-4. 주사액제의 제조1-4. Preparation of Injection
적당한 주사용 염화나트륨 BP에 감초 뿌리 추출물 2.5 ㎍/㎖와 노랑민들레 추출물 10 ㎍/㎖의 혼합물 또는 감초 뿌리 추출물 6.25 ㎍/㎖와 노랑민들레 지상부 추출물 6.25 ㎍/㎖의 혼합물을 용해시키고, 생성된 용액의 pH를 묽은염산 BP를 사용하여 pH 3.5로 조절하고, 주사용 염화나트륨 BP(최대 1 ㎖)를 사용하여 용적을 조절하여 충분히 혼합하였다. 용액을 투명 유리로 된 5 ㎖ 타입 I 앰플 중에 충전시키고, 유리를 용해시킴으로써 공기의 상부 격자하에 봉입시키고, 120 ℃에서 15분 이상 오토클래이브시켜 살균하여 주사액제를 제조하였다.Dissolve a mixture of 2.5 μg / ml licorice root extract and 10 μg / ml of yellow dandelion extract or 6.25 μg / ml of licorice root extract and 6.25 μg / ml yellow dandelion ground extract in a suitable injectable sodium chloride BP, and The pH was adjusted to pH 3.5 using dilute hydrochloric acid BP, and the volume was adjusted thoroughly using sodium chloride BP (up to 1 mL) for injection and mixed well. The solution was filled into a 5 ml Type I ampoule made of clear glass, encapsulated under an upper grid of air by dissolving the glass, and sterilized by autoclaving at 120 ° C. for at least 15 minutes to prepare an injection solution.
제조예 2: 건강식품의 제조Preparation Example 2 Preparation of Health Food
2-1. 조리용 양념의 제조2-1. Preparation of Cooking Seasonings
감초 뿌리 추출물과 노랑민들레 지상부 추출물을 4:1 내지 1:4의 중량비로 혼합한 혼합물을 0.2 ~ 10 중량%로 첨가하여 건강 증진용 조리용 양념을 제조하였다.A mixture for mixing licorice root extract and yellow dandelion ground extract in a weight ratio of 4: 1 to 1: 4 was added at 0.2 to 10% by weight to prepare a cooking sauce for health promotion.
2-2. 토마토 2-2. tomato 케찹ketchup 및 소스의 제조 And preparation of sauces
감초 뿌리 추출물과 노랑민들레 지상부 추출물을 1:1 내지 1:4의 중량비로 혼합한 혼합물 0.2 ~ 1.0 중량%를 토마토 케찹 또는 소스에 첨가하여 건강 증진용 토마토 케찹 또는 소스를 제조하였다.A health promotion tomato ketchup or sauce was prepared by adding 0.2 to 1.0 wt% of a mixture of licorice root extract and yellow dandelion ground extract at a weight ratio of 1: 1 to 1: 4 to tomato ketchup or sauce.
2-3. 밀가루 식품의 제조2-3. Manufacture of Flour Food
감초 뿌리 추출물과 노랑민들레 지상부 추출물을 1:1 내지 1:4의 중량비로 혼합한 혼합물 0.1 ~ 5.0 중량%를 밀가루에 첨가하고, 이 혼합물을 이용하여 빵, 케이크, 쿠키, 크래커 및 면류를 제조하여 건강 증진용 식품을 제조하였다.0.1 to 5.0% by weight of the mixture of licorice root extract and yellow dandelion ground extract in a weight ratio of 1: 1 to 1: 4 was added to the flour, and bread, cake, cookies, crackers and noodles were prepared using the mixture. Health promoting foods were prepared.
2-4. 스프 및 육즙 (gravies)의 제조2-4. Manufacture of soups and gravy
감초 뿌리 추출물과 노랑민들레 지상부 추출물을 4:1 내지 1:4의 중량비로 혼합한 혼합물 0.1 ~ 1.0 중량%를 스프 및 육즙에 첨가하여 건강 증진용 육가공 제품, 면류의 수프 및 육즙을 제조하였다.A mixture of licorice root extract and yellow dandelion ground extract in a weight ratio of 4: 1 to 1: 4 was added to the soup and broth to prepare a health-producing meat product, soup of noodles and broth.
2-5. 그라운드 비프 (ground beef)의 제조2-5. Preparation of Ground Beef
감초 뿌리 추출물과 노랑민들레 지상부 추출물을 1:1 내지 1:4의 중량비로 혼합한 혼합물 10 중량%를 그라운드 비프에 첨가하여 건강 증진용 그라운드 비프를 제조하였다.Health promotion ground beef was prepared by adding 10 wt% of a mixture of licorice root extract and yellow dandelion ground extract in a weight ratio of 1: 1 to 1: 4 to ground beef.
2-6. 유제품 (dairy products)의 제조2-6. Manufacture of dairy products
감초 뿌리 추출물과 노랑민들레 지상부 추출물을 1:1 내지 1:4의 중량비로 혼합한 혼합물 0.1 ~ 1.0 중량%를 우유에 첨가하고, 상기 우유를 이용하여 버터 및 아이스크림과 같은 다양한 유제품을 제조하였다.0.1 to 1.0% by weight of the mixture of licorice root extract and yellow dandelion ground extract in a weight ratio of 1: 1 to 1: 4 was added to milk, and various dairy products such as butter and ice cream were prepared using the milk.
2-7. 선식의 제조2-7. Manufacture of wire
현미, 보리, 찹쌀, 율무를 공지된 방법으로 알파화시켜 건조시킨 것을 배전한 후 분쇄기로 입도 60 메쉬의 분말로 제조하였다.Brown rice, barley, glutinous rice, and yulmu were alphad by a known method, and then dried and roasted to prepare a powder having a particle size of 60 mesh.
검정콩, 검정깨, 들깨도 공지된 방법으로 쪄서 건조시킨 것을 배전한 후 분쇄기로 입도 60 메쉬의 분말로 제조하였다.Black beans, black sesame seeds, and perilla were also steamed and dried in a known manner, and then roasted to prepare a powder having a particle size of 60 mesh.
감초 뿌리 추출물과 노랑민들레 지상부 추출물을 1:1 내지 1:4의 중량비로 혼합한 혼합물을 진공 농축기에서 감압농축하고, 분무, 열풍 건조기로 건조하여 얻은 건조물을 분쇄기로 입도 60 메쉬로 분쇄하여 건조분말을 얻었다.The mixture obtained by mixing licorice root extract and yellow dandelion ground extract in a weight ratio of 1: 1 to 1: 4 was concentrated under reduced pressure in a vacuum concentrator, and dried by spraying and hot air dryer. Got.
상기에서 제조한 곡물류, 종실류 및 감초 추출물의 건조분말을 다음의 비율로 배합하여 제조하였다.The dry powders of the grains, seeds and licorice extracts prepared above were formulated in the following ratios.
곡물류 (현미 30 중량%, 율무 15 중량%, 보리 20 중량%),Cereals (30% brown rice, 15% barley, 20% barley),
종실류 (들깨 7 중량%, 검정콩 8 중량%, 검정깨 7 중량%),Seeds (7% by weight perilla, 8% by weight black beans, 7% by weight black sesame seeds),
감초 뿌리 추출물과 노랑민들레 지상부 추출물이 1:1 내지 1:4의 중량비로 혼합된 혼합물의 건조분말 (1 중량%),Dry powder (1% by weight) of the mixture of licorice root extract and yellow dandelion ground extract in a weight ratio of 1: 1 to 1: 4,
영지 (0.5 중량%), 및Ganoderma lucidum (0.5% by weight), and
지황 (0.5 중량%)Foxglove (0.5 wt%)
2-8. 탄산음료의 제조2-8. Preparation of Carbonated Drinks
설탕 5~10%, 구연산 0.05 ~ 0.3 %, 카라멜 0.005 ~ 0.02 %, 비타민 C 0.1 ~ 1 %의 첨가물을 혼합하고, 여기에 79 ~ 94 %의 정제수를 섞어서 시럽을 만들었다. 상기에서 제조한 시럽을 85 ~ 98 ℃에서 20 ~ 180초 동안 살균하여 냉각수와 1 : 4의 비율로 혼합시킨 다음, 탄산가스를 0.5 ~ 0.82 % 주입하여 감초 뿌리 추출물과 노랑민들레 지상부 추출물이 1:1 내지 1:4의 중량비로 혼합된 혼합물을 함유하는 탄산음료를 제조하였다.Syrup was prepared by mixing 5-10% of sugar, 0.05-0.3% citric acid, 0.005-0.02% caramel, 0.1-1% vitamin C, and 79-94% purified water. The syrup prepared above was sterilized at 85 to 98 ° C. for 20 to 180 seconds, mixed with cooling water at a ratio of 1: 4, and then 0.5 to 0.82% of carbon dioxide was injected to give the licorice root extract and the yellow dandelion ground extract 1: A carbonated beverage containing a mixture was prepared in a weight ratio of 1 to 1: 4.
2-9. 건강음료의 제조2-9. Manufacture of health drinks
액상과당 (0.5 %), 올리고당 (2 %), 설탕 (2 %), 식염 (0.5 %), 물 (75 %)과 같은 부재료에 감초 뿌리 추출물과 노랑민들레 지상부 추출물이 1:1 내지 1:4의 중량비로 혼합된 혼합물을 균질하게 배합하여 순간 살균을 한 후 이를 유리병, 패트병 등 소포장 용기에 포장하여 건강음료를 제조하였다.Licorice root extract and yellow dandelion ground extract were found in subsidiary materials such as liquid fructose (0.5%), oligosaccharide (2%), sugar (2%), salt (0.5%) and water (75%). The mixture was mixed homogeneously in a weight ratio of to sterilize the instant and then packaged in a small packaging container such as glass bottles, plastic bottles to prepare a healthy beverage.
Claims (10)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170104866A KR102019974B1 (en) | 2017-08-18 | 2017-08-18 | A composition for preventing, improving or treating alcoholic gastro-intestinal disease comprising the extracts from licorice and dandelion |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170104866A KR102019974B1 (en) | 2017-08-18 | 2017-08-18 | A composition for preventing, improving or treating alcoholic gastro-intestinal disease comprising the extracts from licorice and dandelion |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20190019660A KR20190019660A (en) | 2019-02-27 |
| KR102019974B1 true KR102019974B1 (en) | 2019-09-10 |
Family
ID=65561052
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020170104866A KR102019974B1 (en) | 2017-08-18 | 2017-08-18 | A composition for preventing, improving or treating alcoholic gastro-intestinal disease comprising the extracts from licorice and dandelion |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102019974B1 (en) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101307501B1 (en) * | 2007-10-22 | 2013-10-15 | 인제대학교 산학협력단 | Composition for preventing or treating immune disease comprising dandelion water extract as an active ingredient |
-
2017
- 2017-08-18 KR KR1020170104866A patent/KR102019974B1/en active IP Right Grant
Non-Patent Citations (1)
| Title |
|---|
| 논문1* |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20190019660A (en) | 2019-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3991742A1 (en) | Coronavirus therapeutic agent comprising elaeocarpus sylvestris extract as active ingredient | |
| KR101464337B1 (en) | Composition for anti-obesity comprising extract of Diospyros lotus as effective component | |
| KR101902932B1 (en) | A composition for preventing, improving or treating alcoholic gastritis of the extracts from the aerial parts except flower and root of Cirsium japonicum and Taraxacum coreanum | |
| US20130041023A1 (en) | Composition for Preventing or Treating Rotavirus Infection Comprising Licorice Extract | |
| KR101018403B1 (en) | composition comprising the extract of soybean leaves for the prevention?delay or treatment of gout | |
| KR101292931B1 (en) | Composition Comprising Hedyotis diffusa extract for prevention or treatment of nonalcoholic fatty liver disease | |
| KR20140129492A (en) | Compositions Comprising a Leaf Extract of Cudrania tricuspidata for the Prevention and Treatment of Arthritis disease | |
| KR102019974B1 (en) | A composition for preventing, improving or treating alcoholic gastro-intestinal disease comprising the extracts from licorice and dandelion | |
| KR102414431B1 (en) | A composition for improving, preventing and treating of diabetes mellitus | |
| KR101070476B1 (en) | Composition containing extract of black onion for prevention and treatment of Gout or Hyperuricemia | |
| KR102302045B1 (en) | A composition for improving, preventing and treating of liver diseases comprising Milk thistle and onion | |
| KR101248378B1 (en) | Pharmaceutical composition for arthritis treatment and prevention | |
| KR101282356B1 (en) | Composition comprising Acanthopanacis Cortex butanol fraction for preventing or treating gastrointestinal disease | |
| KR100760386B1 (en) | Composition comprising the extract of ACP mixed crude drugs for preventing and treating arthritis | |
| KR101077916B1 (en) | Pharmaceutical compositions for prevention and treatment of obesity comprising extract of eremochloa ophiuroides as an active ingredient | |
| KR100888068B1 (en) | Compositions for suppressing obesity | |
| KR101531922B1 (en) | Composition containing improvement of gastric disease by using the ethanolic extract of Rumex acetosa L. | |
| KR101724587B1 (en) | Composition for treating, improving or preventing liver injury and liver dysfunction | |
| JP6063499B2 (en) | Pharmaceutical composition for prevention and treatment of male infertility containing dough yellow, eggplant, agarwood, persimmon, a mixture of ginseng and honey as active ingredients | |
| KR20200107524A (en) | Pharmaceutical Composition Comprising Fraction of Ginseng Extract for Preventing or Treating Liver Diseases | |
| KR100538983B1 (en) | Pharmaceutical composition comprising the crude drug extract for improving liver function | |
| KR20140026737A (en) | A composition comprising the powder of fermented curcuma longa l. for protecting alcoholic liver damage | |
| KR102302047B1 (en) | Composition for hepatoprotective and ameliorating hangover | |
| KR20050107362A (en) | Health improving food containing an extract of the root bark of ulmus davidiana var | |
| KR20220053243A (en) | Pharmaceutical composition comprising the extract of glehnia littoralis as an effective component for prevention or treatment of diabetes and health functional food comprising the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |